Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. (Q53142244)
Jump to navigation
Jump to search
scientific article published on 18 April 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. |
scientific article published on 18 April 2014 |
Statements
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. (English)
Noriyuki Akutsu
Shigeru Sasaki
Hideyasu Takagi
Masayo Motoya
Masahiro Shitani
Mai Igarashi
Daisuke Hirayama
Hideki Wakasugi
Hiroyuki Yamamoto
Hiroyuki Kaneto
Kazuhiko Yonezawa
Atsushi Yawata
Takeya Adachi
Yasuo Hamamoto
Yasuhisa Shinomura
18 April 2014
20
1
105-110
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference